SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-271923
Filing Date
2023-11-07
Accepted
2023-11-07 07:39:00
Documents
16
Period of Report
2023-11-07
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d471928d8k.htm   iXBRL 8-K 29983
2 EX-1.1 d471928dex11.htm EX-1.1 194240
3 EX-5.1 d471928dex51.htm EX-5.1 9260
7 GRAPHIC g471928dsp01.jpg GRAPHIC 2420
8 GRAPHIC g471928dsp01aa.jpg GRAPHIC 12421
  Complete submission text file 0001193125-23-271923.txt   433973

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA sage-20231107.xsd EX-101.SCH 2847
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE sage-20231107_lab.xml EX-101.LAB 17235
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sage-20231107_pre.xml EX-101.PRE 10810
10 EXTRACTED XBRL INSTANCE DOCUMENT d471928d8k_htm.xml XML 3291
Mailing Address 215 FIRST STREET CAMBRIDGE MA 02142
Business Address 215 FIRST STREET CAMBRIDGE MA 02142 617-299-8380
Sage Therapeutics, Inc. (Filer) CIK: 0001597553 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36544 | Film No.: 231381603
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences